

SYNAPTICS Inc  
Form 10-Q  
February 07, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 29, 2018

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_.

Commission file number 000-49602

SYNAPTICS INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

77-0118518  
(I.R.S. Employer  
Identification No.)

1251 McKay Drive

San Jose, California 95131

(Address of principal executive offices) (Zip code)

(408) 904-1100

Edgar Filing: SYNAPTICS Inc - Form 10-Q

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Number of shares of Common Stock outstanding at February 1, 2019: 34,403,114

SYNAPTICS INCORPORATED

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED DECEMBER 29, 2018

TABLE OF CONTENTS

	Page
<u>Part I. Financial Information</u>	
Item 1. <u>Condensed Consolidated Financial Statements (Unaudited):</u>	3
<u>Condensed Consolidated Balance Sheets—December 31, 2018 and June 30, 2018</u>	3
<u>Condensed Consolidated Statements of Operations—Three and Six Months Ended December 31, 2018 and 2017</u>	4
<u>Condensed Consolidated Statements of Comprehensive Income/(Loss)—Three and Six Months Ended December 31, 2018 and 2017</u>	5
<u>Condensed Consolidated Statements of Cash Flows—Six Months Ended December 31, 2018 and 2017</u>	6
<u>Notes to Condensed Consolidated Financial Statements</u>	7
Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	21
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	31
Item 4. <u>Controls and Procedures</u>	31
<u>Part II. Other Information</u>	
Item 1. <u>Legal Proceedings</u>	32
Item 1A. <u>Risk Factors</u>	32
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	32
Item 6. <u>Exhibits</u>	33
<u>Signatures</u>	34



## PART I—FINANCIAL INFORMATION

## ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

## SYNAPTICS INCORPORATED AND SUBSIDIARIES

## CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except par value and share amounts)

(unaudited)

	December 31, 2018	June 30, 2018
<b>ASSETS</b>		
Current Assets:		
Cash and cash equivalents	\$283.0	\$301.0
Accounts receivable, net of allowances of \$2.1 and \$1.8 at December 31, 2018 and June 30, 2018, respectively	326.0	289.1
Inventories	145.7	131.2
Prepaid expenses and other current assets	35.1	18.2
Total current assets	789.8	739.5
Property and equipment at cost, net of accumulated depreciation of \$130.4 and \$127.4 at December 31, 2018 and June 30, 2018, respectively	106.0	117.8
Goodwill	372.8	372.8
Acquired intangibles, net	181.2	219.2
Non-current other assets	49.8	50.5
	\$1,499.6	\$1,499.8
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current Liabilities:		
Accounts payable	\$172.6	\$156.9
Accrued compensation	23.2	25.4
Income taxes payable	11.6	13.1
Acquisition-related liabilities	-	8.7
Other accrued liabilities	91.9	79.7
Total current liabilities	299.3	283.8
Convertible notes, net	459.4	450.7
Other long-term liabilities	36.7	36.0
Total liabilities	795.4	770.5
Stockholders' Equity:		
Common stock:		
\$0.001 par value; 120,000,000 shares authorized,	0.1	0.1

Edgar Filing: SYNAPTICS Inc - Form 10-Q

63,803,544 and 62,889,679 shares issued, and 34,313,668 and 35,249,803 shares

outstanding, at December 31, 2018 and June 30, 2018, respectively

Additional paid-in capital	1,232.3	1,195.2
Treasury stock: 29,489,876 and 27,639,876 common treasury shares at		
December 31, 2018 and June 30, 2018, respectively, at cost	(1,151.2)	(1,073.9)
Accumulated other comprehensive income	-	1.5
Retained earnings	623.0	606.4
Total stockholders' equity	704.2	729.3
	\$1,499.6	\$1,499.8

See accompanying notes to condensed consolidated financial statements (unaudited).

## SYNAPTICS INCORPORATED AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share data)

(unaudited)

	Three Months Ended December 31,		Six Months Ended December 31,	
	2018	2017	2018	2017
Net revenue	\$425.5	\$430.4	\$843.1	\$847.8
Cost of revenue	275.7	315.2	552.4	618.2
Gross margin	149.8	115.2	290.7	229.6
Operating expenses:				
Research and development	84.2	92.2	174.3	179.3
Selling, general, and administrative	35.6	37.4	69.4	77.7
Acquired intangibles amortization	2.9	3.0	5.8	7.1
Restructuring costs	2.1	6.6	10.4	6.4
Total operating expenses	124.8	139.2	259.9	270.5
Operating income/(loss)	25.0	(24.0)	30.8	(40.9)
Interest and other expense, net	(4.3)	(4.7)	(6.2)	(10.7)
Income/(loss) before provision for income taxes and				
equity investment loss	20.7	(28.7)	24.6	(51.6)
Provision for income taxes	7.5	53.3	7.2	56.5
Equity investment loss	(0.4)	(0.4)	(0.8)	(0.8)
Net income/(loss)	\$12.8	\$(82.4)	\$16.6	\$(108.9)
Net income/(loss) per share:				
Basic	\$0.37	\$(2.42)	\$0.48	\$(3.22)
Diluted	\$0.36	\$(2.42)	\$0.47	\$(3.22)
Shares used in computing net income/(loss) per share:				
Basic	34.5	34.1	34.8	33.8
Diluted	35.1	34.1	35.6	33.8

See accompanying notes to condensed consolidated financial statements (unaudited).





SYNAPTICS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)

(in millions)

(unaudited)

	Three Months Ended December 31,		Six Months Ended December 31,	
	2018	2017	2018	2017
Net income/(loss)	\$12.8	\$(82.4)	\$16.6	\$(108.9)
Other comprehensive loss:				
Change in unrealized net gain on investment	-	-	(1.5)	-
Net current period-other comprehensive loss	-	-	(1.5)	-
Comprehensive income/(loss)	\$12.8	\$(82.4)	\$15.1	\$(108.9)

See accompanying notes to condensed consolidated financial statements (unaudited).

## SYNAPTICS INCORPORATED AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

(unaudited)

	Six Months Ended December 31,	
	2018	2017
Cash flows from operating activities		
Net income/(loss)	\$ 16.6	\$(108.9)
Adjustments to reconcile net income/(loss) to net cash provided by operating activities:		
Share-based compensation costs	32.9	34.3
Depreciation and amortization	19.2	20.1
Acquired intangibles amortization	38.0	43.3
Deferred taxes	(4.5 )	22.7
Amortization of convertible debt discount and issuance costs	8.7	8.4
Amortization of debt issuance costs	0.3	1.4
Impairment recovery on investments	(2.8 )	-
Arbitration settlement	(1.9 )	-
Equity investment loss	0.8	0.8
Foreign currency remeasurement (gain)/loss	0.2	0.1
Changes in operating assets and liabilities, net of acquisitions:		
Accounts receivable, net	(31.7 )	30.0
Inventories	(14.5 )	70.1
Prepaid expenses and other current assets	(17.0 )	18.4
Other assets	2.6	(5.5 )
Accounts payable	19.5	(27.6 )
Accrued compensation	(2.2 )	(5.4 )
Acquisition-related liabilities	(6.8 )	-
Income taxes payable	(0.4 )	7.6
Other accrued liabilities	6.5	(6.6 )
Net cash provided by operating activities	63.5	103.2
Cash flows from investing activities		
Acquisition of businesses, net of cash and cash equivalents acquired	-	(395.9)
Proceeds from sales of investments	2.8	-
Purchases of property and equipment	(11.2 )	(19.5 )
Purchase of intangible assets	-	(7.7 )
Net cash used in investing activities	(8.4 )	(423.1)
Cash flows from financing activities		
Proceeds from issuance of convertible debt, net of issuance costs	-	514.5
Payment of debt	-	(220.0)
Purchases of treasury stock	(77.3 )	(93.6 )
Proceeds from issuance of shares	11.4	9.2

Edgar Filing: SYNAPTICS Inc - Form 10-Q

Payment of debt issuance costs	-	(1.1 )
Payroll taxes for deferred stock and market stock units	(7.2 )	(4.6 )
Net cash provided by/(used in) financing activities	(73.1 )	204.4
Effect of exchange rate changes on cash and cash equivalents	-	(0.1 )
Net decrease in cash and cash equivalents	(18.0 )	(115.6)
Cash and cash equivalents at beginning of period	301.0	367.8
Cash and cash equivalents at end of period	\$283.0	\$252.2
Supplemental disclosures of cash flow information		
Cash paid for taxes	\$14.3	\$18.1
Cash refund on taxes	\$5.2	\$1.0
Non-cash investing and financing activities:		
Purchases of property and equipment in current liabilities	\$2.8	\$3.4
Common stock issued pursuant to acquisition	\$-	\$39.1

See accompanying notes to condensed consolidated financial statements (unaudited)

SYNAPTICS INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, and U.S. generally accepted accounting principles, or U.S. GAAP. Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations. In our opinion, the financial statements include all adjustments, which are of a normal and recurring nature and necessary for the fair presentation of the results of the interim periods presented. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future period. These financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2018.

The consolidated financial statements include our financial statements and those of our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.

Our fiscal year is the 52- or 53-week period ending on the last Saturday in June. Our fiscal 2019 is a 52-week period ending June 29, 2019, and our fiscal 2018 was a 53-week period ending on June 30, 2018. The fiscal periods presented in this report are 13-week and 26-week periods for the three and six months ended December 29, 2018, respectively, and 13-week and 27-week periods for the three and six months ended December 30, 2017, respectively. For simplicity, the accompanying condensed consolidated financial statements have been shown as ending on calendar quarter end dates as of and for all periods presented, unless otherwise indicated.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, allowance for doubtful accounts, cost of revenue, inventories, loss on purchase commitments, product warranty, accrued liabilities, share-based compensation costs, provision for income taxes, deferred income tax asset valuation allowances, uncertain tax positions, goodwill, intangible assets, investments and loss contingencies. We base our estimates on historical experience, applicable laws and regulations, and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Foreign Currency Transactions and Foreign Exchange Contracts

The U.S. dollar is our functional and reporting currency. We remeasure our monetary assets and liabilities not denominated in the functional currency into U.S. dollar equivalents at the rate of exchange in effect on the balance sheet date. We measure and record non-monetary balance sheet accounts at the historical rate in effect at the date of transaction. We remeasure foreign currency expenses at the weighted average exchange rate in the month that the

transaction occurred. Our foreign currency transactions and remeasurement gains and losses are included in selling, general, and administrative expenses in the condensed consolidated statements of operations and resulted in net losses of \$0.2 million and \$0.6 million in the three and six months ended December 31, 2018 and net losses of \$0.2 million and \$0.5 million in the three and six months ended December 31, 2017.

## 2. Revenue Recognition

### Change in Accounting Policy

In May 2014, the FASB issued an Accounting Standards Update, or ASU, on revenue from contracts with customers, ASU No. 2014-09, Revenue from Contracts with Customers, or the new revenue standard. The new revenue standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers.

7

---

We adopted the new revenue standard at the beginning of our fiscal 2019, using the modified retrospective method applied to all contracts not completed as of the adoption date. Results for reporting periods ending after our fiscal 2018 are presented under the new revenue standard, while prior reporting periods are not adjusted and continue to be reported in accordance with the previous revenue standard. Recognition of revenue has remained substantially unchanged under the new revenue standard as that under the previous revenue standard. Accordingly, there was no adjustment to the fiscal 2019 opening retained earnings. However, we reclassified certain amounts of incentive items to other accrued liabilities in our condensed consolidated balance sheet as of December 31, 2018, and presented them as part of customer obligations, from the contra accounts receivable due to the adoption of the new revenue standard. Such information is as follows (in millions):

## Condensed Consolidated Balance Sheets

	As of December 31, 2018		
	As reported under new standard	Adjustments	Pro forma as if previous standard was in effect
Accounts receivable, net	\$326.0	\$ (5.1 )	\$320.9
Total assets	1,499.6	(5.1 )	1,494.5
Other accrued liabilities	91.9	(5.1 )	86.8
Total liabilities and stockholders' equity	1,499.6	(5.1 )	1,494.5

## Condensed Consolidated Statement of Cash Flows

	Six Months Ended December 31, 2018		
	As reported under new standard	Adjustments	Pro forma as if previous standard was in effect
Cash flows from operating activities:			
Accounts receivable, net	\$(31.7)	\$ (0.1 )	\$(31.8 )
Other accrued liabilities	6.5	0.1	6.6

## Revenue Recognition

Our revenue is primarily generated from the sale of ASIC chips, either directly to a customer or to a distributor. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to receive in exchange for those goods or services. All of our revenue, except an inconsequential amount, is recognized at a point in time, either on shipment or delivery of the product, depending on customer terms and conditions. We generally warrant our products for a period of 12 months from the date of sale and estimate probable product warranty costs at the time we recognize revenue as the warranty is considered an assurance warranty and not a performance obligation. Non-product revenue is recognized over the same period of time such performance obligations are satisfied. We then select an appropriate method for measuring satisfaction of the performance obligations.

Revenue from sales to distributors is recognized upon shipment of the product to the distributors (sell-in basis). Master sales agreements are in place with certain customers, and these agreements typically contain terms and conditions with respect to payment, delivery, warranty and supply. In the absence of a master sales agreement, we consider a customer's purchase order or our standard terms and conditions to be the contract with the customer.

Our pricing terms are negotiated independently, on a stand-alone basis. In determining the transaction price, we evaluate whether the price is subject to refund or adjustment to determine the net consideration which we expect to receive for the sale of such products. In limited situations, we make sales to certain customers under arrangements where we grant stock rotation rights, price protection and price allowances; variable consideration associated with these rights is expected to be inconsequential. These adjustments and incentives are accounted for as variable consideration, classified as other current liabilities under the new revenue standard and are shown as customer obligations in Note 7 Other Accrued Liabilities. We estimate the amount of variable consideration for such arrangements based on the expected value to be provided to customers, and we do not believe that there will be significant changes to our estimates of variable consideration. When incentives, stock rotation rights, price protection, volume discounts, or price allowances are applicable, they are estimated and recorded in the period the related revenue is recognized. Stock rotation reserves are based on historical return rates and recorded as a reduction to revenue with a corresponding reduction to cost of goods sold for the estimated cost of inventory that is expected to be returned. In limited circumstances we enter into volume based tiered pricing arrangements and we estimate total unit volumes under such arrangement to determine the expected transaction price for the units expected to be transferred. Such arrangements are accounted for as contract liabilities within other accrued liabilities. Sales returns liabilities are recorded as refund liabilities within other accrued liabilities.

Our accounts receivable balance is from contracts with customers and represents our unconditional right to receive consideration from customers. Payments are generally due within three months upon completion of the performance obligation and subsequent invoicing and, therefore, do not include significant financing components. To date, there have been no material impairment losses on accounts receivable. There were no contract assets (i.e., unbilled accounts receivable, deferred commissions) recorded on the condensed consolidated balance sheets in the periods presented. Contract liabilities and refund liabilities were \$6.4 million and \$39.9 million, respectively, as of December 31, 2018 and \$1.1 million and \$31.6 million, respectively, as of the beginning of fiscal 2019. Both contract liabilities and refund liabilities are presented as part of customer obligations in Note 7 Other Accrued Liabilities. During the six months ended December 31, 2018, we recognized \$0.3 million in revenue related to contract liabilities outstanding as of the beginning of fiscal 2019.

We invoice customers for each delivery upon shipment and recognize revenue in accordance with delivery terms. As of December 31, 2018, we did not have any remaining unsatisfied performance obligations with an original duration greater than one year. Accordingly, under the optional exception provided by ASC 606-10-50-14, we do not disclose revenues allocated to future performance obligations of partially completed contracts. We have elected to account for shipping and handling costs as fulfillment costs before the customer obtains control of the goods. We continue to classify shipping and handling costs as a cost of revenue. We have elected to continue to account for collection of all taxes on a net basis.

We incur commission expense that is incremental to obtaining contracts with customers. Sales commissions (which are recorded in the “selling, general and administrative” expense line item in the condensed consolidated statements of operations) are expensed when the product is shipped because such commissions are owed after shipment.

Revenue from contracts with customers disaggregated by geographic area based on customer location and groups of similar products is presented in Note 12 Segment, Customers, and Geographical Information.

### 3. Net Income Per Share



Edgar Filing: SYNAPTICS Inc - Form 10-Q

The computation of basic and diluted net income per share was as follows (in millions, except per share data):

	Three Months Ended December 31, 2018 2017		Six Months Ended December 31, 2018 2017	
<b>Numerator:</b>				
Net income/(loss)	\$12.8	\$(82.4)	\$16.6	\$(108.9)
<b>Denominator:</b>				
Shares, basic	34.5	34.1	34.8	33.8
Effect of dilutive share-based awards	0.6	—	0.8	—
Shares, diluted	35.1	34.1	35.6	33.8
<b>Net income/(loss) per share:</b>				
Basic	\$0.37	\$(2.42)	\$0.48	\$(3.22 )
Diluted	\$0.36	\$(2.42)	\$0.47	\$(3.22 )

9

Our basic net income per share amounts for each period presented have been computed using the weighted average number of shares of common stock outstanding over the period measured. Our diluted net income per share amounts for each period presented include the weighted average effect of potentially dilutive shares. We use the “treasury stock” method to determine the dilutive effect of our stock options, deferred stock units, or DSUs, market stock units, or MSUs, performance stock units, or PSUs, and our convertible notes.

Dilutive net income per share amounts do not include the potential weighted average effect of 1,736,456 and 3,334,776 shares of common stock related to certain share-based awards that were outstanding during the three months ended December 31, 2018 and 2017, respectively, and 1,426,365 and 3,020,056 shares of common stock related to certain share-based awards that were outstanding during the six months ended December 31, 2018, and 2017, respectively. These share-based awards were not included in the computation of diluted net income per share because their effect would have been antidilutive.

#### 4. Fair Value

Financial assets measured at fair value on a recurring basis by level within the fair value hierarchy, consisted of the following (in millions):

	December 31, 2018			June 30, 2018		
	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3
<b>Assets:</b>						
Money market funds	\$259.4	\$ -	\$ -	\$275.2	\$ -	\$ -
Auction rate securities	-	-	-	-	-	1.5
Total available-for-sale securities	\$259.4	\$ -	\$ -	\$275.2	\$ -	\$ 1.5

In our condensed consolidated balance sheets, as of December 31, 2018 and June 30, 2018, money market balances were included in cash and cash equivalents and as of June 30, 2018, auction rate securities, or ARS investments, were included in non-current other assets.

During the six months ended December 31, 2018 we converted our ARS investments to senior surplus notes, under an offering memorandum, which also included a receipt of a small amount of cash and warrants. We sold the senior surplus notes during the six months ended December 31, 2018, resulting in a gain of \$2.8 million. There were no transfers in or out of our Level 1, 2, or 3 assets during the six months ended December 31, 2018 and 2017.

The fair values of our accounts receivable and accounts payable approximate their carrying values because of the short-term nature of those instruments. Intangible assets, property and equipment, and goodwill are measured at fair value on a non-recurring basis if impairment is indicated.

## 5. Inventories

Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value and consisted of the following (in millions):

	December 31, 2018	June 30, 2018
Raw materials and work-in-progress	\$ 111.8	\$105.0
Finished goods	33.9	26.2
	\$ 145.7	\$131.2

We record a write-down, if necessary, to reduce the carrying value of inventory to its net realizable value. The effect of these write-downs is to establish a new cost basis in the related inventory, which we do not subsequently write up. We also record a liability and charge to cost of revenue for estimated losses on inventory we are obligated to purchase from our contract manufacturers when such losses become probable from customer delays, order cancellations, or other factors.

## 6. Acquired Intangibles and Goodwill

## Acquired Intangibles

The following table summarizes the life, the gross carrying value and the related accumulated amortization of our acquired intangible assets as of December 31, 2018 and June 30, 2018 (in millions):

	Weighted Average Life in Years	December 31, 2018			June 30, 2018		
		Gross Carrying Value	Accumulated Amortization	Net Carrying Value	Gross Carrying Value	Accumulated Amortization	Net Carrying Value
Display driver technology	5.3	\$164.0	\$ (132.2	)\$ 31.8	\$164.0	\$ (116.5	)\$ 47.5
Audio and video							
technology	5.5	134.1	(35.9	) 98.2	133.9	(22.8	) 111.1
Fingerprint authentication							
technology	4.7	47.2	(47.2	) -	55.7	(53.7	) 2.0
Customer relationships	4.1	81.8	(44.2	) 37.6	81.8	(38.5	) 43.3
Licensed technology							
and other	4.2	7.7	(2.6	) 5.1	9.0	(3.0	) 6.0
Tradename	7.0	1.8	(0.4	) 1.4	1.9	(0.2	) 1.7
Patents	8.1	4.4	(1.8	) 2.6	4.6	(1.7	) 2.9
Backlog	-	-	-	-	0.5	(0.5	) -
In-process research and							
development	Not applicable	4.5	-	4.5	4.7	-	4.7
Acquired intangibles,							
gross	5.0	\$445.5	\$ (264.3	)\$ 181.2	\$456.1	\$ (236.9	)\$ 219.2

The total amortization expense for the acquired intangible assets was \$18.0 million and \$23.2 million for the three months ended December 31, 2018 and 2017, respectively, and \$38.0 million and \$43.3 million for the six months ended December 31, 2018 and 2017, respectively. During the three months ended December 31, 2018 and 2017, \$15.1 million and \$20.3 million, respectively, and \$32.1 million and \$36.2 million for the six months ended December 31, 2018 and 2017, respectively, of amortization expense was included in our condensed consolidated statements of operations in cost of revenue; the remainder was included in acquired intangibles amortization.

The following table presents expected annual fiscal year aggregate amortization expense as of December 31, 2018 (in millions):

Remainder of 2019	\$36.0
2020	50.5
2021	36.6
2022	32.0
2023	19.5
2024	2.0
Thereafter	0.1
To be determined	4.5
Future amortization	\$181.2

## Goodwill

Goodwill represents the excess of the purchase price over the fair value of net tangible and identifiable intangible assets acquired. There were no changes in our goodwill balance for the six months ended December 31, 2018.

## 7. Other Accrued Liabilities

Other accrued liabilities consisted of the following (in millions):

	December 31, 2018	June 30, 2018
Customer Obligations	\$ 46.3	\$26.4
Inventory obligations	30.1	28.8
Warranty	4.1	5.5
Other	11.4	19.0
	\$ 91.9	\$79.7

Customer obligations include \$6.4 million of contract liabilities and \$39.9 million of refund liabilities as of December 31, 2018, as defined under revenue recognition guidance of the new revenue standard (see Note 2 Revenue Recognition). We reclassified certain amounts of incentive items to other current liabilities in our condensed consolidated balance sheet as of December 31, 2018, and presented them as part of customer obligations, from the contra accounts receivable due to the adoption of the new revenue standard.

## 8. Indemnifications, Contingencies and Legal Proceedings

### Indemnifications

In connection with certain agreements, we are obligated to indemnify the counterparty against third party claims alleging infringement of certain intellectual property rights by us. We have also entered into indemnification agreements with our officers and directors. Maximum potential future payments under these agreements cannot be estimated because these agreements do not have a maximum stated liability. However, historical costs related to these indemnification provisions have not been significant. We have not recorded any liability in our condensed consolidated financial statements for such indemnification obligations.

### Contingencies

We have in the past, and may in the future receive notices from third parties that claim our products infringe their intellectual property rights. We cannot be certain that our technologies and products do not and will not infringe issued patents or other proprietary rights of third parties.

Any infringement claims, with or without merit, could result in significant litigation costs and diversion of management and financial resources, including the payment of damages, which could have a material adverse effect on our business, financial condition, and results of operations.

### Legal Proceedings

In October 2015, Amkor Technology, or Amkor, filed a complaint against us alleging infringement of intellectual property rights and various other claims. In November 2015, we filed an indemnification claim against the former stockholders and option holders of Validity Sensors, Inc., or Validity, to secure our rights under the Agreement and Plan of Reorganization between us and Validity (the “Validity Agreement”). In April 2017, we agreed to settle this case with Amkor on undisclosed terms that include each party licensing and assigning certain intellectual property rights, and cash payments. Settlement costs incurred in connection with this litigation were recorded in our condensed consolidated financial statements in fiscal 2017 and all but an immaterial amount was paid during our fiscal 2017. Pursuant to the Validity Agreement, we offset costs, damages and settlements incurred in connection with our defense and resolution of the complaint with Amkor against the contingent consideration earnout balance of \$8.7 million as of June 30, 2018. In September 2018, we entered into a final order settling the indemnification claim against the former stockholders and option holders of Validity under which we retained \$1.9 million of the earnout balance and paid the remainder of \$6.8 million in October 2018.

## 9. Debt

### Convertible Debt

Our convertible debt consists of an original \$525 million aggregate principal amount of 0.50% convertible senior notes due 2022, or the Notes, which were issued in a private placement transaction. The net proceeds from the Notes, after deducting discounts, were \$514.5 million.

12

---

The Notes bear interest at a rate of 0.50% per year, which is payable semi-annually in arrears, on June 15 and December 15 of each year. The Notes are senior unsecured obligations and rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to any of our liabilities that are not so subordinated; effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

The Notes mature on June 15, 2022, or the Maturity Date, unless earlier repurchased, redeemed or converted.

Holders may convert all or any portion of their Notes, in multiples of \$1,000 principal amounts, at their option at any time prior to the close of business on the business day immediately preceding March 15, 2022 under certain defined circumstances.

On or after March 15, 2022 until the close of business on the business day immediately preceding the Maturity Date, holders may convert all or any portion of their Notes, in multiples of \$1,000 principal amounts, at the option of the holder. Upon conversion, we will pay or deliver, at our election, shares of common stock, cash, or a combination of cash and shares of common stock.

The conversion rate for the Notes is initially 13.6947 shares of common stock per \$1,000 principal amount of Notes (equivalent to an initial conversion price of approximately \$73.02 per share of common stock). The conversion rate is subject to adjustment in certain circumstances.

Upon the occurrence of a fundamental change (as defined in the Notes indenture), holders of the Notes may require us to repurchase for cash all or a portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest up to, but excluding, the fundamental change repurchase date.

We may not redeem the Notes prior to June 20, 2020. We may redeem for cash all or any portion of the Notes, at our option, on or after June 20, 2020, if the last reported sale price of our common stock, as determined by us, has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest up to, but excluding, the redemption date. Our policy is to settle the principal amount of our Notes with cash upon conversion or redemption.

As of the issuance date of the Notes, we recorded \$82.1 million of the principal amount to equity, representing the debt discount for the difference between our estimated nonconvertible debt borrowing rate of 4.39% and the coupon rate of the Notes of 0.50% using a five-year life, which coincides with the term of the Notes. In addition, we allocated the total of \$11.1 million of debt issuance costs, consisting of the Initial Purchaser's discount of \$10.5 million and legal, accounting, and printing costs of \$579,000, pro rata, to the equity and debt components of the Notes, or \$1.9 million and \$9.2 million, respectively. The debt discount and the debt issuance costs allocated to the debt component of the Notes are amortized as interest expense using the effective interest method over five years.

The contractual interest expense and amortization of discount on the Notes for the six months ended December 31, 2018, were as follows (in millions):



	Six Months Ended December 31, 2018
Interest expense	\$ 1.3
Amortization of discount and debt issuance costs	8.7
Total interest	\$ 10.0

The unamortized amounts of the debt issuance costs and discount associated with the Notes as of December 31, 2018 were \$6.6 million and \$59.0 million, respectively.

#### Revolving Credit Facility

In September 2017, we entered into an Amendment and Restatement Agreement, or the Agreement, with the lenders that are party thereto, or the Lenders, and Wells Fargo Bank, National Association, as administrative agent for the Lenders. The Agreement terminated our prior term loan arrangement and provides for a revolving credit facility in a principal amount of up to \$200 million,

which includes a \$20 million sublimit for letters of credit and a \$20 million sublimit for swingline loans. Under the terms of the Agreement, we may, subject to the satisfaction of certain conditions, request increases in the revolving credit facility commitments in an aggregate principal amount of up to \$100 million to the extent existing or new lenders agree to provide such increased or additional commitments, as applicable. Proceeds under the revolving credit facility are available for working capital and general corporate purposes. As of December 31, 2018, there is no balance outstanding under the revolving credit facility.

The revolving credit facility is required to be repaid in full on the earlier of (i) September 27, 2022 and (ii) the date 91 days prior to the Maturity Date of the Notes if the Notes have not been refinanced in full by such date. Debt issuance costs of \$2.3 million relating to the revolving credit facility will be amortized over 60 months.

Our obligations under the Agreement are guaranteed by the material domestic subsidiaries of our company, subject to certain exceptions (such material subsidiaries, together with our company, collectively, the Credit Parties). The obligations of the Credit Parties under the Agreement and the other loan documents delivered in connection therewith are secured by a first priority security interest in substantially all of the existing and future personal property of the Credit Parties, including, without limitation, 65% of the voting capital stock of certain of the Credit Parties' direct foreign subsidiaries, subject to certain exceptions.

The revolving credit facility bears interest at our election of a Base Rate plus an Applicable Margin or LIBOR plus an Applicable Margin. Swingline loans bear interest at a Base Rate plus an Applicable Margin. The Base Rate is a floating rate that is the greater of the Prime Rate, the Federal Funds Rate plus 50 basis points, or LIBOR plus 100 basis points. The Applicable Margin is based on a sliding scale which ranges from 0.25 to 100 basis points for Base Rate loans and 100 basis points to 175 basis points for LIBOR loans. We are required to pay a commitment fee on any unused commitments under the Agreement which is determined on a leverage-based sliding scale ranging from 0.175% to 0.25% per annum. Interest and fees are payable on a quarterly basis.

Under the Agreement, there are various restrictive covenants, including three financial covenants which limit the consolidated total leverage ratio, or leverage ratio, the consolidated interest coverage ratio, or interest coverage ratio, a restriction which places a limit on the amount of capital expenditures that may be made in any fiscal year, a restriction that permits up to \$50 million per fiscal quarter of accounts receivable financings, and sets the Specified Leverage Ratio. The leverage ratio is the ratio of debt as of the measurement date to earnings before interest, taxes, depreciation and amortization, or EBITDA, for the four consecutive quarters ending with the quarter of measurement. The current leverage ratio shall not exceed 3.50 to 1.00 provided that for the four fiscal quarters ending after the date of a material acquisition, such maximum leverage ratio shall be adjusted to 3.75 to 1.00, and thereafter, shall not be more than 3.50 to 1.00. The interest coverage ratio is EBITDA to interest expense for the four consecutive quarters ending with the quarter of measurement. The interest coverage ratio must not be less than 3.50 to 1.0 during the term of the Agreement. The Specified Leverage Ratio is the ratio used in determining, among other things, whether we are permitted to make dividends and/or prepay certain indebtedness, at a fixed ratio of 3.00 to 1.00. As of the end of the quarter, we were in compliance with the restrictive covenants.

## 10. Share-Based Compensation

Share-based compensation and the related tax benefit recognized in our condensed consolidated statements of operations were as follows (in millions):

Edgar Filing: SYNAPTICS Inc - Form 10-Q

	Three Months Ended December 31, 2018		Six Months Ended December 31, 2017	
	2018	2017	2018	2017
Cost of revenue	\$0.8	\$0.7	\$1.7	\$1.4
Research and development	8.5	9.8	16.8	18.9
Selling, general, and administrative	6.9	7.3		